3,826 Shares in Quest Diagnostics Incorporated $DGX Purchased by Diversify Wealth Management LLC

Diversify Wealth Management LLC acquired a new stake in Quest Diagnostics Incorporated (NYSE:DGX) in the 1st quarter, HoldingsChannel reports. The fund acquired 3,826 shares of the medical research company’s stock, valued at approximately $724,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Key Financial Inc increased its stake in shares of Quest Diagnostics by 1,728.6% during the first quarter. Key Financial Inc now owns 128 shares of the medical research company’s stock worth $25,000 after buying an additional 121 shares during the period. Quattro Advisors LLC acquired a new stake in Quest Diagnostics during the 4th quarter worth $25,000. JFS Wealth Advisors LLC increased its position in shares of Quest Diagnostics by 114.3% during the fourth quarter. JFS Wealth Advisors LLC now owns 150 shares of the medical research company’s stock worth $26,000 after purchasing an additional 80 shares in the last quarter. Harbor Investment Advisory LLC lifted its stake in Quest Diagnostics by 113.7% in the fourth quarter. Harbor Investment Advisory LLC now owns 156 shares of the medical research company’s stock valued at $27,000 after buying an additional 83 shares during the last quarter. Finally, DV Equities LLC acquired a new stake in Quest Diagnostics during the 4th quarter worth $27,000. 88.06% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have weighed in on DGX shares. Weiss Ratings upgraded Quest Diagnostics from a “buy (b)” rating to a “buy (b+)” rating in a research note on Thursday, July 9th. Wall Street Zen upgraded shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Barclays lifted their price target on Quest Diagnostics from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 22nd. UBS Group upped their target price on Quest Diagnostics from $210.00 to $220.00 and gave the company a “neutral” rating in a research note on Wednesday, April 22nd. Finally, Truist Financial boosted their target price on shares of Quest Diagnostics from $220.00 to $225.00 and gave the company a “hold” rating in a research note on Wednesday, April 22nd. Seven investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat, Quest Diagnostics presently has an average rating of “Moderate Buy” and a consensus price target of $217.17.

Quest Diagnostics Stock Up 3.8%

NYSE:DGX opened at $209.34 on Friday. The company has a market capitalization of $23.17 billion, a price-to-earnings ratio of 23.13, a price-to-earnings-growth ratio of 2.40 and a beta of 0.58. The stock has a 50-day simple moving average of $200.05 and a 200 day simple moving average of $196.02. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.08 and a current ratio of 1.18. Quest Diagnostics Incorporated has a one year low of $165.19 and a one year high of $219.20.

Quest Diagnostics (NYSE:DGX) last posted its quarterly earnings results on Tuesday, April 21st. The medical research company reported $2.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.37 by $0.13. Quest Diagnostics had a net margin of 9.07% and a return on equity of 15.60%. The company had revenue of $2.90 billion for the quarter, compared to the consensus estimate of $2.83 billion. During the same period last year, the firm posted $1.94 EPS. The company’s revenue for the quarter was up 9.2% on a year-over-year basis. Quest Diagnostics has set its FY 2026 guidance at 10.630-10.830 EPS. Sell-side analysts predict that Quest Diagnostics Incorporated will post 10.72 EPS for the current fiscal year.

Quest Diagnostics Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 22nd. Stockholders of record on Wednesday, July 8th will be paid a $0.86 dividend. The ex-dividend date of this dividend is Wednesday, July 8th. This represents a $3.44 annualized dividend and a dividend yield of 1.6%. Quest Diagnostics’s dividend payout ratio is presently 38.01%.

Insider Activity

In other Quest Diagnostics news, SVP Karthik Kuppusamy sold 8,147 shares of the business’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $200.00, for a total transaction of $1,629,400.00. Following the sale, the senior vice president directly owned 13,510 shares in the company, valued at approximately $2,702,000. The trade was a 37.62% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO J. E. Davis sold 10,000 shares of the business’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $194.14, for a total value of $1,941,400.00. Following the completion of the sale, the chief executive officer directly owned 132,423 shares in the company, valued at $25,708,601.22. This represents a 7.02% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.88% of the stock is currently owned by company insiders.

About Quest Diagnostics

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.